Compass Therapeutics, Inc. (CMPX) Key Metrics
CMPX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $154.9M
- Enterprise value
- $40.5M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 269.3
- Price / book
- 1.3 10-yr median 1.6
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.91
CMPX key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCMPX valuation Price multiples at each fiscal year-end price.
CMPX returns How much profit the business earns on the capital it uses.
CMPX per-share figures Results divided by the shares outstanding at year-end.
CMPX financial health Debt, liquidity and how easily interest is covered.
CMPX efficiency & capital use Working capital cycle and where the cash goes.
CMPX valuation history
CMPX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CMPX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CMPX cash returned to shareholders
CMPX price vs earnings per share
CMPX key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $846.8M | $198.8M | $198.2M | $529.1M | $199.3M | — | — | — |
| Enterprise value | $647.7M | $78.7M | $47.4M | $345.4M | $58.8M | — | — | — |
| Price / sales | — | 233.9 | — | — | — | — | — | — |
| Price / book | 4.3 | 1.6 | 1.3 | 2.9 | 1.4 | — | — | — |
| EV / sales | — | 92.6 | — | — | — | — | — | — |
| Earnings yield | −7.9% | −24.8% | −21.4% | −7.4% | −41.2% | — | — | — |
| Free cash flow yield | −5.8% | −22.6% | −20.5% | −6.5% | −10.7% | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | 0.0% | 0.0% | 0.0% | — | — | — |
| Share price at fiscal year-end | $5.37 | $1.45 | $1.56 | $5.03 | $3.17 | — | — | — |
| Per share | ||||||||
| Revenue per share | $0.00 | $0.01 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Earnings per share | −$0.42 | −$0.36 | −$0.33 | −$0.37 | −$1.31 | −$0.52 | −$0.67 | — |
| Operating cash flow per share | −$0.31 | −$0.33 | −$0.32 | −$0.32 | −$0.31 | −$0.48 | −$0.61 | — |
| Free cash flow per share | −$0.31 | −$0.33 | −$0.32 | −$0.33 | −$0.34 | −$0.48 | −$0.62 | — |
| Cash per share | $1.32 | $0.92 | $1.20 | $1.77 | $2.30 | $0.84 | $0.49 | — |
| Book value per share | $1.25 | $0.91 | $1.17 | $1.73 | $2.23 | $0.71 | −$2.28 | — |
| Tangible book value per share | $1.25 | $0.91 | $1.17 | $1.73 | $2.23 | $0.71 | −$2.28 | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.02 | $0.00 | $0.01 | — |
| Debt per share | $0.06 | $0.05 | $0.01 | $0.03 | $0.06 | $0.17 | $0.29 | — |
| Shares outstanding | 157.7M | 137.1M | 127.0M | 105.2M | 62.9M | 56.2M | 52.1M | — |
| Change in shares outstanding | +15.0% | +7.9% | +20.8% | +67.3% | +11.8% | +7.9% | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −41.3% | −36.1% | −25.7% | −24.4% | −91.3% | — | — | — |
| Return on assets (ROA) | −36.9% | −33.2% | −23.8% | −22.2% | −79.9% | −71.7% | −73.1% | −59.2% |
| Return on tangible assets | −30.3% | −35.2% | −27.1% | −19.6% | −53.4% | −56.8% | −114.4% | −59.2% |
| Financial health | ||||||||
| Total debt | $9.8M | $6.6M | $1.7M | $2.9M | $4.0M | $9.3M | $14.9M | $14.8M |
| Cash & short-term investments | $208.9M | $126.7M | $152.5M | $186.6M | $144.5M | $47.1M | $25.3M | $57.5M |
| Net debt | −$199.1M | −$120.1M | −$150.7M | −$183.7M | −$140.5M | −$37.7M | −$10.4M | −$42.8M |
| Debt / equity | 0.05 | 0.05 | 0.01 | 0.02 | 0.03 | 0.23 | — | — |
| Debt / assets | 0.04 | 0.05 | 0.01 | 0.01 | 0.03 | 0.18 | 0.49 | 0.23 |
| Current ratio | 15.02 | 14.96 | 19.73 | 12.05 | 13.84 | 4.97 | 2.67 | 6.96 |
| Quick ratio | 15.02 | 14.96 | 19.73 | 12.05 | 13.84 | 4.97 | 2.67 | 6.96 |
| Interest coverage | — | — | — | -17.7 | -221.3 | -30.6 | -27.7 | -50.0 |
| Working capital | $195.9M | $123.9M | $146.1M | $178.6M | $136.5M | $40.1M | $16.4M | $50.4M |
| Invested capital | −$2.3M | $5.1M | −$2.2M | −$2.0M | −$399,000 | $2.2M | −$129.0M | −$127.5M |
| Tangible asset value | $196.8M | $125.2M | $148.5M | $181.6M | $140.1M | $39.9M | −$118.6M | −$84.8M |
| Net current asset value | $187.0M | $117.6M | $145.5M | $176.8M | $133.4M | $38.2M | −$122.7M | −$90.5M |
| Graham net-net per share | $1.18 | $0.81 | $1.13 | $1.61 | $2.08 | $0.62 | −$2.37 | — |
| Capital allocation | ||||||||
| Share buybacks (net) | — | — | $159 | $0 | $0 | $0 | — | — |
| Capex / revenue | — | 5.2% | — | — | — | — | — | — |
| Capex / depreciation | 0.02 | 0.03 | 0.02 | 0.11 | 0.97 | 0.04 | 0.22 | 1.05 |
| Stock-based compensation / revenue | — | 1,007.1% | — | — | — | — | — | — |
| R&D / revenue | — | 4,981.4% | — | — | — | — | — | — |
| SG&A / revenue | — | 1,780.4% | — | — | — | — | — | — |
| Efficiency | ||||||||
| Days payables outstanding | 475.3 | — | 721.5 | 407.3 | 216.7 | 128.3 | 203.1 | 328.7 |
| Receivables turnover | — | — | — | 0.00 | — | — | — | — |
| Payables turnover | 0.77 | 0.00 | 0.51 | 0.90 | 1.68 | 2.84 | 1.80 | 1.11 |
| Asset turnover | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | — | $320,000 | — | — | — | — |
| Average payables | $1.9M | $3.2M | $3.7M | $2.1M | $964,000 | $845,000 | $1.2M | $1.7M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from CMPX's annual financial statements (latest annual report filed March 5, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CMPX valuation and financial ratios
Compass Therapeutics earned a return on equity of −41.3% in fiscal 2025. It ended the year with $9.8 million of debt and $208.9 million in cash and short-term investments, a net cash position of $199.1 million.
See the CMPX income statement, the CMPX chart for price history, or the CMPX stock overview for the latest quote and news.
CMPX key metrics FAQ
What is Compass Therapeutics's return on equity?
Compass Therapeutics's return on equity (ROE) was −41.3% in fiscal 2025: net income of -$66.5 million on average shareholders' equity of $161.0 million.
How much debt does Compass Therapeutics have?
Compass Therapeutics had total debt of $9.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.05 and more cash than debt.
What is Compass Therapeutics's free cash flow yield?
Compass Therapeutics generated -$49.2 million of free cash flow in fiscal 2025, a free cash flow yield of −5.8% on its market value at year-end ($846.8 million).
What is Compass Therapeutics's current ratio?
Compass Therapeutics's current ratio was 15.02 at the end of fiscal 2025: current assets were 15.02 times current liabilities.